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Athracycline antibiotics (such as daunorubicin, doxorubicin or epirubicin) belong 
to the most common terapeutics of both solid tumors and hematological malignities. 
Unfortunately the serious and life-threatening adverse effect cardiotoxicity 
compromises their clinical usefulness. The only approved protection against 
anthracycline cardiotoxicity so far is dexrazoxane. Despite the outstanding 
cardioprotective ability, dexrazoxane use is very limited mainly due to its possible side 
effects. So we were directed towards synthesis of dexrazoxane analogues with better 
pharmacological properties.  
The aim of this diploma thesis was to assess the antiproliferative activity of novel 
analogues of both dexrazoxane (MK-15 and ES-5) and ADR-925 (JR-159 and KH-
TA4) and their influence on the antiproliferative effectiveness of anthracyclines. 
Moreover, we aimed to study their chelating properties and their inhibition of the 
topoisomerase II in solution. 
We tested the antiproliferative activity of the novel analogues using the promyelotic 
leukemia HL-60 cell line. Cellular viability was assessed with MTT test after 72 hours 
of incubation of cells with novel analogues alone or in combination with daunorubicin 
on 96-well plates at a density of 10,000 cells per well. Iron displacement from its 
complex with anthracyclines was measured spectrophotometrically by the changes 
of the daunorubicin-Fe complex specific absorbation at 600 nm over time.The results 
show statistically significant drop in the HL-60 proliferation caused by dexrazoxane and 
KH-TA4. The novel agents (10 and 100 µM) did not compromise the antiproliferative 
action of 15 nM daunorubicin (IC50 value). From the novel analogues, only JR-159 was 
able to at least partially displace iron from its daunorubicin complex. The relaxation 
activity of topoisomerase II was inhibited by 100 μM dexrazoxane. 
